-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1469 Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia with t(16;21)(p11;q22)

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, AML, Clinical Research, Diseases, Registries, Myeloid Malignancies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

?? ??1*, Yoshimitsu Shimomura, MD, PhD1,2*, Hiroki Mizumaki, MD PhD3*, Masamitsu Yanada4*, Shohei Mizuno, MD, PhD5*, Naoyuki Uchida6, Noriko Doki7, Ayumu Ito, MD, PhD8*, Masatsugu Tanaka, MD9*, Tetsuya Nishida, MD PhD10*, Yuta Katayama, MD, PhD11, Satoshi Yoshihara, MD, PhD12, Tetsuya Eto13*, Koji Kawamura, MD, PhD14*, Makoto Onizuka15, Takahiro Fukuda8*, Marie Ohbiki16,17,18*, Yoshiko Atsuta19* and Takaaki Konuma, MD, PhD20*

1Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
2Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Suita, Japan
3Department of Hematology, Kanazawa University, Kanazawa, JPN
4Department of Hematology and Oncology, Nagoya City University East Medical Center, Nagoya, Japan
5Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan
6Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL, Tokyo, Japan
7Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
8Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
9Department of Hematology, Kanagawa Cancer Center, Kanagawa, Japan
10Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan
11Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan
12Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan
13Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
14Division of Hematology and Clinical Laboratory Medicine, Tottori University Hospital, Yonago, Japan
15Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan
16Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan
17Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan
18Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
19The Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan
20Department of Hematology and Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Background: The chromosomal translocation t(16;21)(p11;q22), which results in the FUS::ERG fusion gene, is a rare but nonrandom genetic abnormality in acute myeloid leukemia (AML). According to a recent cytogenetic stratification, the sole abnormality of t(16;21)(p11;q22) is classified as intermediate-risk, while limited previous case reports and case series suggest that AML with t(16;21)(p11;q22) may be a subtype with a poor prognosis. However, evidence regarding allogeneic hematopoietic stem cell transplantation (HSCT) for AML with t(16;21)(p11;q22) is lacking.

Methods: We conducted a retrospective study of AML patients aged ≥16 years who underwent their first allogeneic HSCT between 1986 and 2021 using the Transplant Registry Unified Management Program of the Japan Society for Transplantation and Cellular Therapy and the Japanese Data Center for Hematopoietic Cell Transplantation. We included AML patients with t(16;21)(p11;q22) and those without the translocation as the reference cohort. Patients with favorable-risk karyotypes were excluded from the study. Our data had some patients without information regarding the breakpoint of the t(16;21) translocation. We considered them as harboring t(16;21)(p11;q22) in our analysis because t(16;21)(q24;q22), the other candidate for translocation, is notably rare in adult AML patients. Additionally, we performed a sensitivity analysis to evaluate patient characteristics and transplant outcomes to check for misclassifications. We then compared patients with and without t(16;21)(p11;q22) in each chromosomal risk group (intermediate- and poor-risk groups). We estimated the 3-year overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), and cumulative incidence of non-relapse mortality (NRM) using the Kaplan–Meier and Gray methods. The impact of t(16;21)(p11;q22) was estimated using multivariable Cox proportional hazard and Fine–Gray models. The covariates included age, sex, etiology, disease status, extramedullary lesions, hematopoietic cell transplantation-specific comorbidity index, donor source, conditioning regimen intensities, and prophylaxis of graft versus host disease.

Results: We enrolled 15,432 patients aged 16–85 years (median, 51 years). There were 104 patients with t(16;21)(p11;q22). For these patients, ages ranged from 18-70 years (median, 41 years) and 58 patients (56.3%) were complete remission at the time of transplantation. Regarding transplant outcomes, the 3-year PFS and OS were 5.3% (95% CI: 2.1–13.1%) and 11.2% (95% CI: 6.2–20.3%), respectively. Furthermore, 81 patients were classified as intermediate-risk and 23 as poor-risk due to additional poor prognostic chromosomal abnormalities. Next, we compared their transplant outcomes with those of the reference cohort (intermediate-risk patients: 11,340; poor-risk patients: 3988). For the intermediate-risk group, the 3-year PFS was 5.8% (95% CI: 2.1–15.9%) in patients with t(16;21)(p11;q22) vs 47.5% (95% CI: 46.5–48.4%) in the reference cohort (P < 0.001). In the multivariable analysis, the adjusted hazard ratio (HR) for PFS was 2.66 (95% CI: 1.97–3.60, P < 0.001). The 3-year OS, CIR, and NRM were 12.2% (95% CI: 6.3–23.7%) vs 51.4% (95% CI: 50.5–52.4%) (P < 0.001), 57.9% (95% CI: 45.2–68.6%) vs 28.6% (95% CI: 27.7–29.4%) (P < 0.001), and 36.3% (95% CI: 25.0–47.7%) vs 24.0% (95% CI: 23.2–24.8%) (P = 0.16) for the patients with t(16;21)(p11;q22) vs the reference cohort, respectively. For the poor-risk groups, the 3-year PFS was 4.4% (95% CI: 0.6–29.6%) in patients with t(16;21)(p11;q22) vs 26.6% (95% CI: 25.2–28.0%) in the reference cohort, respectively (P = 0.249). The adjusted HR for PFS was 1.90 (95% CI: 1.16–3.12, P = 0.011). The 3-year OS, CIR and NRM were 8.7% (95% CI: 2.3–32.7%) vs 30.2% (95% CI: 28.8–31.7%) (P = 0.592), 82.6% (95% CI: 56.8–93.7%) vs 49.5% (95% CI: 47.9–51.0%) (P = 0.012), and 13.0% (95% CI: 2.5–32.6%) vs 24.0% (95% CI: 22.6–25.3%) (P = 0.17), for the patients with t(16;21)(p11;q22) vs the reference cohort, respectively.

Conclusions: AML patients with t(16;21)(p11;q22) demonstrate poor outcomes after allogeneic HSCT, primarily because of high relapse rates. These findings highlight the need to label this genetic mutation as a poor-risk group and develop novel therapeutic strategies to improve the poor prognosis.

Disclosures: Mizuno: Hayashikane Sangyo: Research Funding; Janssen pharmaceutical: Honoraria. Uchida: Astellas Pharma Inc.: Consultancy; CSL Behring: Honoraria; JCR Pharmaceuticals Co.: Research Funding; MSD (Merck & Co. Inc.): Honoraria; Daiichi Sankyo Co.: Honoraria; SymBio Pharmaceuticals: Honoraria; Kyowa Kirin Co.: Honoraria; Sumitomo Pharma Co.: Research Funding; Nippon Boehringer Ingelheim Co.: Research Funding; Asahi Kasei Pharma Co.: Honoraria; Takeda Pharmaceutical Co.: Consultancy; Chugai Pharmaceutical Co.: Research Funding; Fuji Pharma Co.: Research Funding; Astellas Pharma Inc.: Honoraria; AstraZeneca: Honoraria; AbbVie GK: Honoraria; Otsuka Pharmaceutical Co.: Honoraria; Takeda Pharmaceutical Co.: Honoraria; Chugai Pharmaceutical Co.: Honoraria; Nippon Shinyaku Co.: Honoraria; Novartis Pharma Co.: Honoraria. Yoshihara: Janssen Pharmaceutical K.K.: Honoraria; CHUGAI PHARMACEUTICAL Co., Ltd.: Research Funding; Novartis Pharma K.K.: Honoraria; Bristol-Myers Squibb Co: Honoraria. Atsuta: Novartis Pharma KK: Speakers Bureau; Meiji Seika Pharma Co., Ltd.: Honoraria; Janssen Pharmaceutical K.K.: Honoraria; Otsuka Pharmaceutical Co., Ltd: Speakers Bureau; JCR Pharmaceuticals Co., Ltd.: Consultancy; CHUGAI PHARMACEUTICAL CO., LTD.: Speakers Bureau.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH